A subfertile patient diagnosed with testicular carcinoma in situ by immunocytological staining for AP-2gamma in semen samples: case report
- PMID: 15650041
- DOI: 10.1093/humrep/deh759
A subfertile patient diagnosed with testicular carcinoma in situ by immunocytological staining for AP-2gamma in semen samples: case report
Abstract
The incidence of testicular cancer is rising. Despite a high cure rate, efforts should be made to obtain diagnosis at the pre-invasive intratubular carcinoma in situ (CIS) stage, as the disease is potentially lethal and treatment has severe side-effects, especially regarding reproductive function. CIS diagnosis is presently only possible by a surgical biopsy of the testis. Immunocytological staining for transcription factor activator protein (AP-2gamma), previously identified as a marker for neoplastic germ cells, was performed in centrifuged samples of ejaculates obtained from 104 andrological patients, including patients with testicular cancer and subfertility. Cells positive for AP-2gamma were found only in semen samples from patients diagnosed a priori with testicular neoplasms and, surprisingly, in a 23 year old control subject with oligozoospermia and no symptoms of a germ cell tumour. Testicular biopsies performed during the follow-up of this patient revealed widespread CIS in one testicle, thus proving a potential diagnostic value of the new marker. For the first time, a patient without clinical symptoms of testicular neoplasia was diagnosed at the pre-invasive CIS stage using a new, simple method based on immunocytological staining of a semen sample for AP-2gamma, a novel marker for CIS. The value of this method for diagnostic use in the clinic requires further careful validation in a large series of patients and controls, but the preliminary results are promising.
Similar articles
-
Transcription factor AP-2gamma is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors.Clin Cancer Res. 2004 Dec 15;10(24):8521-30. doi: 10.1158/1078-0432.CCR-04-1285. Clin Cancer Res. 2004. PMID: 15623634
-
Application of stem cell markers in search for neoplastic germ cells in dysgenetic gonads, extragonadal tumours, and in semen of infertile men.Cancer Treat Rev. 2008 Jun;34(4):348-67. doi: 10.1016/j.ctrv.2007.12.007. Epub 2008 Mar 4. Cancer Treat Rev. 2008. PMID: 18289797 Review.
-
Screening of subfertile men for testicular carcinoma in situ by an automated image analysis-based cytological test of the ejaculate.Int J Androl. 2011 Aug;34(4 Pt 2):e21-30; discussion e30-1. doi: 10.1111/j.1365-2605.2011.01192.x. Epub 2011 Jun 22. Int J Androl. 2011. PMID: 21696398
-
Towards a non-invasive method for early detection of testicular neoplasia in semen samples by identification of fetal germ cell-specific markers.Hum Reprod. 2007 Jan;22(1):167-73. doi: 10.1093/humrep/del320. Epub 2006 Aug 18. Hum Reprod. 2007. PMID: 16920726
-
Epidemiological and clinical aspects of carcinoma in situ of the testis.Eur Urol. 1993;23(1):104-10; discussion 111-4. Eur Urol. 1993. PMID: 8477770 Review.
Cited by
-
Intratubular germ cell neoplasms of the testis and bilateral testicular tumors: clinical significance and management options.Indian J Urol. 2010 Jan-Mar;26(1):64-71. doi: 10.4103/0970-1591.60454. Indian J Urol. 2010. PMID: 20535289 Free PMC article.
-
Etiology and early pathogenesis of malignant testicular germ cell tumors: towards possibilities for preinvasive diagnosis.Asian J Androl. 2015 May-Jun;17(3):381-93. doi: 10.4103/1008-682X.148079. Asian J Androl. 2015. PMID: 25791729 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical